[시장보고서]비낭포성 섬유증 기관지확장증 시장 : 세계 산업 규모, 점유율, 동향, 기회 및 예측 - 치료별, 진단별, 최종 용도별, 지역별, 경쟁별 세분화(2020-2030년)

비낭포성 섬유증 기관지확장증 시장 : 세계 산업 규모, 점유율, 동향, 기회 및 예측 - 치료별, 진단별, 최종 용도별, 지역별, 경쟁별 세분화(2020-2030년)

Non-Cystic Fibrosis Bronchiectasis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment, By Diagnosis, By End use, By Region and Competition, 2020-2030F

상품코드 : 1886353

리서치사 : TechSci Research

발행일 : 2025년 12월

페이지 정보 : 영문 185 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,500

￦ 6,708,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500

￦ 8,199,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000

￦ 11,926,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

세계의 비낭포성 섬유증 기관지확장증 시장은 2024년에 37억 1,000만 달러로 평가되며, 2030년까지 CAGR 5.30%로 성장하며, 50억 6,000만 달러에 달할 것으로 예측됩니다. 비낭성 섬유화 기관지확장증(NCFB) 세계 시장은 기도의 영구적인 확장 및 비후를 특징으로 하는 만성 폐질환을 대상으로 합니다. 이는 낭포성 섬유증과 달리 점액 배출 장애와 반복적인 호흡기 감염을 유발합니다. 이 시장은 주로 만성 호흡기 질환의 전 세계 유병률 증가와 더불어 고해상도 CT 스캔 등 진단 기술의 눈부신 발전으로 인해 보다 빠르고 정확한 질병 파악이 가능해짐에 따라 성장세를 보이고 있습니다.

시장 개요
예측 기간	2026-2030
시장 규모 : 2024년	37억 1,000만 달러
시장 규모 : 2030년	50억 6,000만 달러
CAGR : 2025-2030년	5.30%
가장 빠르게 성장하는 부문	외과수술
최대 시장	북미

주요 시장 성장 촉진요인

비낭성 섬유증 기관지확장증(NCFB)의 전 세계 유병률 증가가 주요 시장 성장 촉진요인으로 꼽히며, 진단 및 치료 자원에 대한 수요를 직접적으로 증가시키고 있습니다. 이러한 추세는 진단 기술의 발전, 임상의의 인식 향상, 그리고 NCFB의 다양한 병인에 대한 이해의 심화에 의해 촉진되고 있습니다.

주요 시장 과제

비낭포성 섬유증성 기관지확장증에 대한 특정 질환에 대한 치료제가 제한적이라는 점이 시장 확대에 큰 제약으로 작용하고 있습니다. 현재의 치료 접근법은 근본적인 질환의 진행을 다루기보다는 재발성 감염과 같은 증상과 합병증 관리에 주안점을 두고 있습니다.

주요 시장 동향

질병 변형 치료 및 생물제제의 개발은 세계 비낭성 섬유증 기관지확장증 시장에서 중요한 진화를 보여주고 있으며, 증상 치료에서 질병 진행을 직접적으로 변화시키는 개입으로 전환하고 있습니다. 이 초점에는 염증을 감소시키거나 박테리아의 정착을 억제하도록 설계된 첨단 생물제제 및 저분자 화합물이 포함됩니다.

시장 규모·예측
- 금액별
시장 점유율·예측
- 치료별(외과수술, 물리치료, 백신 접종, 기도 약물 요법, 항생제, 기타)
- 진단별(CT 스캔, 기관지경 검사, 흉부 X선, 폐기능 검사, 객담 배양 검사, 혈액검사, 기타)
- 최종 용도별(병원·진료소, 외래 진료 센터, 기타)
- 지역별
- 기업별(2024)
시장 맵

제6장 북미의 비낭포성 섬유증 기관지확장증 시장 전망

시장 규모·예측
시장 점유율·예측
북미 : 국가별 분석
- 미국
- 캐나다
- 멕시코

제7장 유럽의 비낭포성 섬유증 기관지확장증 시장 전망

시장 규모·예측
시장 점유율·예측
유럽 : 국가별 분석
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인

제8장 아시아태평양의 비낭포성 섬유증 기관지확장증 시장 전망

시장 규모·예측
시장 점유율·예측
아시아태평양 : 국가별 분석
- 중국
- 인도
- 일본
- 한국
- 호주

제9장 중동 및 아프리카의 비낭포성 섬유증 기관지확장증 시장 전망

시장 규모·예측
시장 점유율·예측
중동 및 아프리카 : 국가별 분석
- 사우디아라비아
- 아랍에미리트
- 남아프리카공화국

제10장 남미의 비낭포성 섬유증 기관지확장증 시장 전망

시장 규모·예측
시장 점유율·예측
남미 : 국가별 분석
- 브라질
- 콜롬비아
- 아르헨티나

제11장 시장 역학

촉진요인
과제

제12장 시장 동향과 발전

합병·인수
제품 출시
최근 동향

제13장 세계의 비낭포성 섬유증 기관지확장증 시장 : SWOT 분석

제14장 Porter's Five Forces 분석

업계내 경쟁
신규 참여의 가능성
공급업체의 힘
고객의 힘
대체품의 위협

제15장 경쟁 구도

Novartis AG
Pfizer Inc.
Bayer AG
Viatris Inc.
Teva Pharmaceutical Industries Ltd.
GSK plc
F. Hoffmann-La Roche Ltd.
Sun Pharmaceutical Industries Ltd.
Aurobindo Pharma Ltd.
Dr. Reddy's Laboratories Ltd.

제16장 전략적 제안

제17장 조사회사 소개·면책사항

KSA

영문 목차

영문목차

The Global Non-Cystic Fibrosis Bronchiectasis Market, valued at USD 3.71 Billion in 2024, is projected to experience a CAGR of 5.30% to reach USD 5.06 Billion by 2030. The Global Non-Cystic Fibrosis Bronchiectasis (NCFB) market addresses a chronic lung condition characterized by the permanent dilation and thickening of the airways, distinct from cystic fibrosis, which leads to impaired mucus clearance and recurrent respiratory infections. The market is primarily driven by the increasing global prevalence of chronic respiratory diseases, alongside significant advancements in diagnostic technologies, such as high-resolution CT scans, facilitating earlier and more accurate disease identification.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 3.71 Billion
Market Size 2030	USD 5.06 Billion
CAGR 2025-2030	5.30%
Fastest Growing Segment	Surgery
Largest Market	North America

Key Market Drivers

The increasing global prevalence of non-cystic fibrosis bronchiectasis (NCFB) stands as a primary market driver, directly raising demand for diagnostic and therapeutic resources. This trend is fueled by advancements in diagnostic technologies, heightened clinician awareness, and a deeper understanding of NCFB's diverse etiologies. NCFB's chronic and progressive nature, often involving recurrent infections, necessitates continuous medical management. As diagnostic methods become more precise, leading to earlier identification, recorded prevalence rates steadily increase.

Key Market Challenges

The limited availability of specific, disease-modifying therapies for Non-Cystic Fibrosis Bronchiectasis significantly constrains market expansion. Current treatment approaches predominantly focus on managing symptoms and complications, such as recurrent infections, rather than addressing the underlying disease progression. This reliance on symptomatic or off-label treatments creates a substantial unmet medical need and restricts the development of a dedicated market segment for truly transformative interventions. Pharmaceutical companies face reduced incentives for significant investment in a therapeutic area where targets for disease modification are not well-defined or approved pathways are limited.

Key Market Trends

The development of disease-modifying and biologic therapies signifies a pivotal evolution in the Global Non-Cystic Fibrosis Bronchiectasis Market, shifting beyond symptomatic management to interventions that directly alter disease progression. This focus includes advanced biologic agents and small molecules designed to reduce inflammation or disrupt bacterial colonization. According to the American Thoracic Society (ATS) 2025 International Conference, in May 2025, the average initial hospitalization for NCFBE patients was 7.1 days, costing 22,355 USD, highlighting the substantial burden new treatments aim to alleviate.

Key Market Players

Novartis AG
Pfizer Inc.
Bayer AG
Viatris Inc.
Teva Pharmaceutical Industries Ltd.
GSK plc
F. Hoffmann-La Roche Ltd.
Sun Pharmaceutical Industries Ltd.
Aurobindo Pharma Ltd.
Dr. Reddy's Laboratories Ltd.

Report Scope:

In this report, the Global Non-Cystic Fibrosis Bronchiectasis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Non-Cystic Fibrosis Bronchiectasis Market, By Treatment:

Surgery
Physiotherapy
Vaccination
Airway pharmacotherapy
Antibiotics
Others

Non-Cystic Fibrosis Bronchiectasis Market, By Diagnosis:

CT scan
Bronchoscopy
Chest X-ray
Lung function
Sputum culture test
Blood tests
Others

Non-Cystic Fibrosis Bronchiectasis Market, By End use:

Hospitals & Clinics
Ambulatory Care Centers
Others

Non-Cystic Fibrosis Bronchiectasis Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Non-Cystic Fibrosis Bronchiectasis Market.

Available Customizations:

Global Non-Cystic Fibrosis Bronchiectasis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Non-Cystic Fibrosis Bronchiectasis Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Treatment (Surgery, Physiotherapy, Vaccination, Airway pharmacotherapy, Antibiotics, Others)
- 5.2.2. By Diagnosis (CT scan, Bronchoscopy, Chest X-ray, Lung function, Sputum culture test, Blood tests, Others)
- 5.2.3. By End use (Hospitals & Clinics, Ambulatory Care Centers, Others)
- 5.2.4. By Region
- 5.2.5. By Company (2024)
5.3. Market Map

6. North America Non-Cystic Fibrosis Bronchiectasis Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Treatment
- 6.2.2. By Diagnosis
- 6.2.3. By End use
- 6.2.4. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Non-Cystic Fibrosis Bronchiectasis Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Treatment
    - 6.3.1.2.2. By Diagnosis
    - 6.3.1.2.3. By End use
- 6.3.2. Canada Non-Cystic Fibrosis Bronchiectasis Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Treatment
    - 6.3.2.2.2. By Diagnosis
    - 6.3.2.2.3. By End use
- 6.3.3. Mexico Non-Cystic Fibrosis Bronchiectasis Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Treatment
    - 6.3.3.2.2. By Diagnosis
    - 6.3.3.2.3. By End use

7. Europe Non-Cystic Fibrosis Bronchiectasis Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Treatment
- 7.2.2. By Diagnosis
- 7.2.3. By End use
- 7.2.4. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Non-Cystic Fibrosis Bronchiectasis Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Treatment
    - 7.3.1.2.2. By Diagnosis
    - 7.3.1.2.3. By End use
- 7.3.2. France Non-Cystic Fibrosis Bronchiectasis Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Treatment
    - 7.3.2.2.2. By Diagnosis
    - 7.3.2.2.3. By End use
- 7.3.3. United Kingdom Non-Cystic Fibrosis Bronchiectasis Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Treatment
    - 7.3.3.2.2. By Diagnosis
    - 7.3.3.2.3. By End use
- 7.3.4. Italy Non-Cystic Fibrosis Bronchiectasis Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Treatment
    - 7.3.4.2.2. By Diagnosis
    - 7.3.4.2.3. By End use
- 7.3.5. Spain Non-Cystic Fibrosis Bronchiectasis Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Treatment
    - 7.3.5.2.2. By Diagnosis
    - 7.3.5.2.3. By End use

8. Asia Pacific Non-Cystic Fibrosis Bronchiectasis Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Treatment
- 8.2.2. By Diagnosis
- 8.2.3. By End use
- 8.2.4. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Non-Cystic Fibrosis Bronchiectasis Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Treatment
    - 8.3.1.2.2. By Diagnosis
    - 8.3.1.2.3. By End use
- 8.3.2. India Non-Cystic Fibrosis Bronchiectasis Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Treatment
    - 8.3.2.2.2. By Diagnosis
    - 8.3.2.2.3. By End use
- 8.3.3. Japan Non-Cystic Fibrosis Bronchiectasis Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Treatment
    - 8.3.3.2.2. By Diagnosis
    - 8.3.3.2.3. By End use
- 8.3.4. South Korea Non-Cystic Fibrosis Bronchiectasis Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Treatment
    - 8.3.4.2.2. By Diagnosis
    - 8.3.4.2.3. By End use
- 8.3.5. Australia Non-Cystic Fibrosis Bronchiectasis Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Treatment
    - 8.3.5.2.2. By Diagnosis
    - 8.3.5.2.3. By End use

9. Middle East & Africa Non-Cystic Fibrosis Bronchiectasis Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Treatment
- 9.2.2. By Diagnosis
- 9.2.3. By End use
- 9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Non-Cystic Fibrosis Bronchiectasis Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Treatment
    - 9.3.1.2.2. By Diagnosis
    - 9.3.1.2.3. By End use
- 9.3.2. UAE Non-Cystic Fibrosis Bronchiectasis Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Treatment
    - 9.3.2.2.2. By Diagnosis
    - 9.3.2.2.3. By End use
- 9.3.3. South Africa Non-Cystic Fibrosis Bronchiectasis Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Treatment
    - 9.3.3.2.2. By Diagnosis
    - 9.3.3.2.3. By End use

10. South America Non-Cystic Fibrosis Bronchiectasis Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Treatment
- 10.2.2. By Diagnosis
- 10.2.3. By End use
- 10.2.4. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Non-Cystic Fibrosis Bronchiectasis Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Treatment
    - 10.3.1.2.2. By Diagnosis
    - 10.3.1.2.3. By End use
- 10.3.2. Colombia Non-Cystic Fibrosis Bronchiectasis Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Treatment
    - 10.3.2.2.2. By Diagnosis
    - 10.3.2.2.3. By End use
- 10.3.3. Argentina Non-Cystic Fibrosis Bronchiectasis Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Treatment
    - 10.3.3.2.2. By Diagnosis
    - 10.3.3.2.3. By End use

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Non-Cystic Fibrosis Bronchiectasis Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Novartis AG
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Pfizer Inc.
15.3. Bayer AG
15.4. Viatris Inc.
15.5. Teva Pharmaceutical Industries Ltd.
15.6. GSK plc
15.7. F. Hoffmann-La Roche Ltd.
15.8. Sun Pharmaceutical Industries Ltd.
15.9. Aurobindo Pharma Ltd.
15.10. Dr. Reddy's Laboratories Ltd.